Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma

2 Apr 2019

Abstract excerpt

BACKGROUND: High-grade serous ovarian cancer is a detrimental disease. Treatment options in patients with a recurrent disease are dependent on BRCA1/2 mutation status since only patients with known BRCA mutation are eligible for treatment with poly(ADP-ribose) polymerase inhibitors (PARPi). The aim of this study was to compare concordance of BRCA mutation analyses from cytological samples (CS) with BRCA mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30940100
DOI: 10.1186/s12885-019-5535-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinomaPMID 30940100Read ↗

Validation of BRCA testing on cytologic samples of high-grade serous carcinoma.Semantic proximity Read ↗

Cytopathological assessment is an accurate method for identifying immunophenotypic features and BRCA1/2 mutations of high-grade serous carcinoma from ascites.Semantic proximity Read ↗

Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease PreventionSemantic proximity Read ↗

Exploring alternatives to tumor tissue for BRCA1/2 next-generation sequencing testing in high-grade serous ovarian cancer: A 34-case series of malignant ascites.Semantic proximity Read ↗

Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer PatientsSemantic proximity Read ↗

High-grade serous ovarian carcinoma and detection of inactivated BRCA genes from biopsy material of Slovak patients.Semantic proximity Read ↗

BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar populationSemantic proximity Read ↗

Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysisSemantic proximity Read ↗

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.Semantic proximity Read ↗

Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube and Primary Peritoneal Cancer: Thai Multi-institutional StudySemantic proximity Read ↗

Ovarian cancer.Semantic proximity Read ↗

Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.